Strain Profile
Save
Clostridium butyricum MIYAIRI 588
◑
Environmental
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Clostridium butyricum MIYAIRI 588 is a spore-forming, butyrate-producing bacterium approved as a probiotic in Japan and studied for its effects on intestinal health. Animal model research has examined intestinal barrier integrity and gut microbiome composition following antibiotic disruption, and in vitro studies have examined antagonistic activity against certain enteric pathogens including Helicobacter pylori and E. coli O157:H7. Genomic screening has examined this strain for toxin genes and antimicrobial sensitivity, and a clinical case report has documented rare bacteremia following major surgery in immunocompromised patients. Human clinical evidence for this specific strain is limited; most data come from preclinical models. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 67 body-system-tagged papers that concern each system. Research coverage, not measured effect.
+4 more systems
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 25 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
85 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2026
RCT
2026
OBSERVATIONAL
2026
ANIMAL
2026
RCT
2026
REVIEW
2026
OBSERVATIONAL
2026
OBSERVATIONAL
2025
RCT
2025
OBSERVATIONAL
2025
OBSERVATIONAL
2025
ANIMAL
2025
OBSERVATIONAL
2025
ANIMAL
2025
ANIMAL
2025
RCT
2024
ANIMAL
2024
OBSERVATIONAL
2024
ANIMAL
2024
OBSERVATIONAL
2023
OBSERVATIONAL
Browse all 85 papers →
First results of a dose-escalation study evaluating Clostridium butyricum MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC).
· Journal of Clinical Oncology
Clinical Outcomes of Metronidazole Monotherapy Versus Metronidazole Plus Clostridium butyricum MIYAIRI 588 Combination Therapy in Non-Severe Clostridioides difficile Infection: A Retrospective Cohort Study
· BioTech
A Probiotic Combination of Limosilactobacillus reuteri and Clostridium butyricum Ameliorates 5‐Fluorouracil‐Induced Intestinal Mucositis in Rats by Strengthening Barrier Integrity and Modulating Immuno‐Microbial Homeostasis
· Journal of Cellular Physiology
Long-term clinical outcomes with Clostridium butyricum MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).
· Journal of Clinical Oncology
Potential Health Benefits of Probiotic Strains of Clostridium butyricum
· Applied Microbiology
Severe Bacteremia Caused by Clostridium butyricum Following Endoscopic Ultrasound‐Guided Peripancreatic Fluid Drainage for Walled‐off Necrosis: A Case Report
· DEN Open
A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancer
· Frontiers in Immunology
Perioperative administration of CBM588 in colorectal cancer radical surgery: A single-center, randomized controlled trial
· Cell Reports Medicine
The effect of probiotic (Clostridium butyricum) on adult patients with atopic dermatitis: a retrospective cohort study from TriNetX
· Human Nutrition & Metabolism
Boosting survival in advanced urothelial carcinoma: The power of CBM588 probiotic and pembrolizumab combination.
· Journal of Clinical Oncology
The Protective Effects of Lactobacillus reuteri Combined With Clostridium butyricum Miyairi 588 on Intestinal Barrier Function, Water Transport, and Oxidative Stress in a Rat Model of 5FU‐Induced Diarrhea
· Food Science & Nutrition
A probiotic bacterium modulates antitumor γδ T-cell responses in lung cancer
· bioRxiv (Cold Spring Harbor Laboratory)
Clostridium butyricum enhances cognitive function in APP/PS1 mice by modulating neuropathology and regulating acetic acid levels in the gut microbiota
· Microbiology Spectrum
Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacy
· International Journal of Cancer
Clostridium butyricum MIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial
· Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
Influence du microbiote intestinal sur la régulation de l'immunosurveillance du cancer
· theses.fr (ABES)
Probiotics-related Clostridium butyricum bacteraemia after COVID-19, confirmed by whole-genome sequencing
· BMJ Case Reports
The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt + Treg and PD-1 blockade efficacy
· Gut Microbes
Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation
· Bone Marrow Transplantation
Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations
· Cancers
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
Source →Long-term clinical outcomes with Clostridium butyricum MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).· Journal of Clinical Oncology · 2026
-
[2]
Source →First results of a dose-escalation study evaluating Clostridium butyricum MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC).· Journal of Clinical Oncology · 2026
-
[3]
Source →Potential Health Benefits of Probiotic Strains of Clostridium butyricum· Applied Microbiology · 2026
-
[4]
PMID 41993168 →A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancer· Frontiers in Immunology · 2026
-
[5]
Source →A probiotic bacterium modulates antitumor γδ T-cell responses in lung cancer· bioRxiv (Cold Spring Harbor Laboratory) · 2025
-
[6]
Source →Boosting survival in advanced urothelial carcinoma: The power of CBM588 probiotic and pembrolizumab combination.· Journal of Clinical Oncology · 2025
-
[7]
PMID 41425719 →Clostridium butyricum MIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial· Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2025
-
[8]
PMID 40633539 →Perioperative administration of CBM588 in colorectal cancer radical surgery: A single-center, randomized controlled trial· Cell Reports Medicine · 2025
-
[9]
Source →The effect of probiotic (Clostridium butyricum) on adult patients with atopic dermatitis: a retrospective cohort study from TriNetX· Human Nutrition & Metabolism · 2025
-
[10]
PMID 38431763 →Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation· Bone Marrow Transplantation · 2024